City of Buffalo Comprehensive Plan 2018-2038

The City of Buffalo Comprehensive Plan 2038 focuses on factors of growth and development including: public participation, development considerations, transportation, economic development, housing, and community facilities. The plan includes a Future Land Use Map, which increases development opportunities and indicates preferred or suitable land use for the city.The City of Buffalo Comprehensive Plan 2038 provides a guide for the future growth of the city. This document was developed by Texas Target Communities in partnership with the City of Buffalo. The document was developed through collaboration with Texas Target Communities (TTC) and a City Advisory Committee representing the City of Buffalo. The purpose of the collaboration was to assess current community conditions, develop goals, objectives, and implementation strategies related to future development & growth strategies, through a public participatory process, in order to help guide the future growth of the City

City of Buffalo Comprehensive Plan 2018-2038

The City of Buffalo Comprehensive Plan 2038 focuses on factors of growth and development including: public participation, development considerations, transportation, economic development, housing, and community facilities. The plan includes a Future Land Use Map, which increases development opportunities and indicates preferred or suitable land use for the city.The City of Buffalo Comprehensive Plan 2038 provides a guide for the future growth of the city. This document was developed by Texas Target Communities in partnership with the City of Buffalo. The document was developed through collaboration with Texas Target Communities (TTC) and a City Advisory Committee representing the City of Buffalo. The purpose of the collaboration was to assess current community conditions, develop goals, objectives, and implementation strategies related to future development & growth strategies, through a public participatory process, in order to help guide the future growth of the City

La Grange Comprehensive Plan 2018 - 2038

In the Fall of 2017, the City of La Grange and Texas Target Communities partnered to create a task force to represent the community. The task force was integral to the planning process, contributing the thoughts, desires, and opinions of community members—as well as their enthusiasm about La Grange’s future. This fifteen-month planning process ended in August 2018. The result of this collaboration is the La Grange Comprehensive Plan, which is the official policy guide for the community’s growth over the next twenty years.La Grange Comprehensive Plan 2018 - 2038 provides a guide for the future growth of the City. This document was developed by Texas Target Communities in partnership with the City of La Grange.Texas Target Communitie

City of Hitchcock Comprehensive Plan 2020-2040

Hitchcock is a small town located in Galveston County (Figure 1.1), nestled up on the Texas Gulf Coast. It lies about 40 miles south-east of Houston. The boundaries of the city encloses an area of land of 60.46 sq. miles, an area of water of 31.64 sq. miles at an elevation just 16 feet above sea level. Hitchcock has more undeveloped land (~90% of total area) than the county combined. Its strategic location gives it a driving force of opportunities in the Houston-Galveston Region.The guiding principles for this planning process were Hitchcock’s vision statement and its corresponding goals, which were crafted by the task force. The goals focus on factors of growth and development including public participation, development considerations, transportation, community facilities, economic development, parks, and housing and social vulnerabilityTexas Target Communitie

The Effects of Photobiomodulation Therapy on the Healing of Eastern Box Turtle (<i>Terrapene carolina</i>) Shells

Photobiomodulation therapy (cold laser or low-level laser therapy) has been evaluated in human and small animal medicine; however, there is a lack of knowledge about the role photobiomodulation therapy could play in reptile rehabilitation and release. This study used a quantifiable unit, Hounsfield units (bone density measurement), in computed tomography (CT) to evaluate if photobiomodulation therapy showed a significant healing difference between groups treated with photobiomodulation and those that were not. This study included 20 eastern box turtles (Terrapene carolina) presented to a rehabilitation center that sustained shell fractures without penetrating the coelom. They all received similar medical treatments, except that the photobiomodulation group received 250 Hz of red light laser for three minutes three times a week for eight weeks. The turtles were evaluated over the course of two months of therapy. Computed tomography scans were performed prior to therapy, at the midpoint of treatment (one month postinjury), and at the end of the study (two months postinjury). The average Hounsfield units of the fractures were evaluated using nonparametric means, the Wilcoxon/Kruskal–Wallis tests (ranked sums), and found that there were no significant differences in shell density between the photobiomodulation and control groups amongst the scans. This study did find that there was a significant difference (p = 0.0455) between the two groups in regard to the width of the fracture between pre- and post-treatment scans. This study found that the photobiomodulation group had a significantly decreased width of the fracture site between pre-treatment and post-treatment measurements, showing that photobiomodulation could be a relatively easy and effective treatment to promote healing of fractured turtle shells

GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review

Abstract Multiple myeloma is a genetically complex and heterogenous malignancy with a 5-year survival rate of approximately 60%. Despite advances in therapy, patients experience cycles of remission and relapse, with each successive line of therapy associated with poorer outcomes; therefore, therapies with different mechanisms of action against new myeloma antigens are needed. G protein–coupled receptor class C group 5 member D (GPRC5D) has emerged as a novel therapeutic target for the treatment of multiple myeloma. We review the biology and target validation of GPRC5D, and clinical data from early phase trials of GPRC5D-targeting bispecific antibodies, talquetamab and forimtamig, and chimeric antigen receptor T cell (CAR-T) therapies, MCARH109, OriCAR-017, and BMS-986393. In addition to adverse events (AEs) associated with T-cell–redirection therapies irrespective of target, a consistent pattern of dermatologic and oral AEs has been reported across several trials of GPRC5D-targeting bispecific antibodies, as well as rare cerebellar events with CAR-T therapy. Additional studies are needed to understand the underlying mechanisms involved in the development of skin- and oral-related toxicities. We review the strategies that have been used to manage these GPRC5D-related toxicities. Preliminary efficacy data showed overall response rates for GPRC5D-targeting T-cell–redirecting therapies were ≥64%; most responders achieved a very good partial response or better. Pharmacokinetics/pharmacodynamics showed that these therapies led to cytokine release and T-cell activation. In conclusion, results from early phase trials of GPRC5D-targeting T-cell–redirecting agents have shown promising efficacy and manageable safety profiles, including lower infection rates compared with B-cell maturation antigen- and Fc receptor-like protein 5-targeting bispecific antibodies. Further clinical trials, including those investigating GPRC5D-targeting T-cell–redirecting agents in combination with other anti-myeloma therapies and with different treatment modalities, may help to elucidate the future optimal treatment regimen and sequence for patients with multiple myeloma and improve survival outcomes. Video Summar

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma

Daratumumab, a human monoclonal antibody targeting CD38, is approved as monotherapy and in combination regimens for patients with multiple myeloma (MM). Currently, daratumumab is administered IV. The phase 1b PAVO (MMY1004) study evaluated subcutaneously administered daratumumab in combination with the recombinant human hyaluronidase PH20 enzyme (rHuPH20) in patients with relapsed or refractory MM. Part 1 of the study, reported here, evaluated a mix-and-deliver (MD) formulation of daratumumab and rHuPH20 (DARA-MD) administered by subcutaneous infusion. Patients received subcutaneous daratumumab according to the approved IV monotherapy dosing schedule at 1200 mg (n 5 8) or 1800 mg (n 5 45). Primary end points were safety and pharmacokinetic (PK) variables. The most common treatment-emergent adverse events with DARA-MD 1200 mg were thrombocytopenia, upper respiratory tract infection, insomnia, and decreased appetite (37.5% each). Anemia (33.3%), upper respiratory tract infection, pyrexia, and diarrhea (26.7% each) were the most common treatment-emergent adverse events with DARA-MD 1800 mg. One patient in the 1200-mg dose group (12.5%) and 11 patients in the 1800-mg dose group (24.4%) experienced infusion-related reactions, which were generally grade 1/2 and typically occurred at the first infusion. The 1800 mg dose achieved similar or greater serum concentrations compared with the 16 mg/kg IV dose. Overall response rates of 25.0% and 42.2% were achieved with 1200-mg and 1800-mg DARA-MD, respectively. Subcutaneous administration of DARA-MD was well tolerated in patients with relapsed or refractory MM, with the 1800-mg dose exhibiting PK concentrations and responses consistent with IV daratumumab in a similar patient population. This study was registered at www.clinicaltrials.gov as #NCT02519452